Unbound MEDLINE

The effect of botulinum toxin type A on full-face intense pulsed light treatment: a randomized, double-blind, split-face study.

Abstract

BACKGROUND
Botulinum toxin type A (BTX) is commonly used in combination therapy, and it has been reported that periocular BTX treatment enhances the aesthetic improvements attained with intense pulsed light (IPL).
OBJECTIVE
The objective was to evaluate if intradermal BTX treatment of the cheeks also enhances the efficacy of IPL.
METHODS AND MATERIALS
Fifteen females enrolled in this prospective, randomized, double-blind, split-face study (14 completed, 1 lost to follow-up). All received standard IPL treatment and were randomly assigned to receive eight 0.1-mL intradermal injections of BTX (BOTOX Cosmetic, Allergan) in one cheek (8 U total dose) and eight injections of saline in the contralateral cheek. Small wrinkles and fine lines, erythema, hyperpigmentation, apparent pore size, skin texture, and overall appearance were evaluated for 8 weeks.
RESULTS
A significantly higher proportion of patients showed improvement in small wrinkles and fine lines with IPL plus BTX than IPL plus saline--93% versus 29% at Week 4 (p=.003). Adjunctive BTX also achieved a greater degree of improvement in erythema (although statistical significance was not achieved). Other efficacy measures showed comparable improvements with both regimens.
CONCLUSION
The adjunctive use of BTX enhances the improvement in small wrinkles and fine lines, and possibly erythema, achieved with IPL alone.

Links

  • Publisher Full Text
  • Authors

    Khoury JG, Saluja R, Goldman MP

    Institution

    Dermatology/La Jolla Inc and La Jolla Spa MD, La Jolla, California 92037, USA.

    Source

    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] 34:8 2008 Aug pg 1062-9

    MeSH

    Adult
    Botulinum Toxins, Type A
    Double-Blind Method
    Face
    Female
    Humans
    Injections
    Middle Aged
    Neurotoxins
    Phototherapy
    Rhytidoplasty
    Tretoquinol

    Pub Type(s)

    Journal Article
    Randomized Controlled Trial
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    18462423